Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 40: 1962-1969, 1994;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenberg, C. S.
Right arrow Articles by Moore, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenberg, C. S.
Right arrow Articles by Moore, B. M.

Clinical Chemistry, Vol 40, 1962-1969, Copyright © 1994 by American Association for Clinical Chemistry

Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2

CS Greenberg, MJ Hursting, BG Macik, TL Ortel, WH Kane and BM Moore
Division of Hematology/Oncology, Duke University Medical Center, Durham, NC 27710.

We have used a monoclonal antibody-based ELISA for plasma prothrombin fragment 1.2 (F1.2) to establish appropriate sample collection and storage conditions for this biomarker of thrombin generation. F1.2 concentrations were not altered by exogenous factor Xa, thrombin, or thromboplastin if blood was collected by routine venipuncture into tubes containing heparin as anticoagulant (but not citrate, acid- citrate-dextrose, EDTA, or oxalate) and if plasma antithrombin III concentration was > or = 30% of normal. Heparinized plasma F1.2 was stable for > or = 8 h at 20-25 degrees C, and if premixed with a stabilizing reagent, for > or = 4 years at -70 degrees C. Mean values for heparinized plasma F1.2 collected and stored by recommended procedures were increased in patients with thrombosis and conditions of increased thrombotic risk, and were sensitive to heparin and oral anticoagulant therapies. We conclude that plasma obtained by routine venipuncture into tubes with heparin as anticoagulant is an appropriate specimen for F1.2 measurements for most patients.


The following articles in journals at HighWire Press have cited this article:


Home page
 CLIN APPL THROMB HEMOSTHome page
T. V. Cuderman, M. Bozic, P. Peternel, and M. Stegnar
Hemostasis Activation in Thrombophilic Subjects With or Without a History of Venous Thrombosis
Clinical and Applied Thrombosis/Hemostasis, January 1, 2008; 14(1): 55 - 62.
[Abstract] [PDF]

Home page
 StrokeHome page
W. M. Feinberg, L. A. Pearce, R. G. Hart, M. Cushman, E. S. Cornell, G. Y.H. Lip, and E. G. Bovill
Markers of Thrombin and Platelet Activity in Patients With Atrial Fibrillation : Correlation With Stroke Among 1531 Participants in the Stroke Prevention in Atrial Fibrillation III Study
Stroke, December 1, 1999; 30(12): 2547 - 2553.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Cushman, C. Legault, E. Barrett-Connor, M. L. Stefanick, C. Kessler, H. L. Judd, P. A. Sakkinen, and R. P. Tracy
Effect of Postmenopausal Hormones on Inflammation-Sensitive Proteins : The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
Circulation, August 17, 1999; 100(7): 717 - 722.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Cushman, B. M. Psaty, E. Macy, E. G. Bovill, E. S. Cornell, L. H. Kuller, and R. P. Tracy
Correlates of Thrombin Markers in an Elderly Cohort Free of Clinical Cardiovascular Disease
Arterioscler Thromb Vasc Biol, September 1, 1996; 16(9): 1163 - 1169.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Association for Clinical Chemistry.